ArticleOncotarget2015
The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- In vitro characterization of cellular responses elicited by endosomal TLR agonists encapsulated in Qβ virus-like particles.BMC immunology · 2025Article
- TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation.BMC immunology · 2024Article
- Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect.Cancers · 2021Article
- Dendritic cell biology and its role in tumor immunotherapy.Journal of hematology & oncology · 2020Review
- Article
- The expression profile of RNA sensors in colorectal cancer and its correlation with cancer stages.Translational cancer research · 2019Article
- Article
- Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.Nanomedicine (London, England) · 2017Review
- Toll-like receptor expression in human non-small cell lung carcinoma: potential prognostic indicators of disease.Oncotarget · 2017Article
- A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.Leukemia · 2017Article
- Anti-tumor Activity of Toll-Like Receptor 7 Agonists.Frontiers in pharmacology · 2017Review
- Differential effects of peptidoglycan on colorectal tumors and intestinal tissue post-pelvic radiotherapy.Oncotarget · 2016Article
- Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.Oncotarget · 2015Article
- CpG Oligonucleotides as Cancer Vaccine Adjuvants.Vaccines · 2015Review
- Linc-POU3F3 promotes cell proliferation in gastric cancer via increasing T-reg distribution.American journal of translational research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treg-induced immunosuppression is now recognized as a key element in enabling tumors to escape immune-mediated destruction. Although topical TLR7 therapies such as imiquimod have been proved successful in the treatment of dermatological malignancy and a number of conditions beyond the FDA-approved indications, the mechanism behind the effect of TLR7 on effector T cell and Treg cell function in cancer immunosurveillance is still not well understood. Here, we found that Loxoribin, one of the TLR7 ligands, could inhibit tumor growth in xenograft models of colon cancer and lung cancer, and these anti-tumor effects of Loxoribin were mediated by promoting CD4⁺T cell proliferation and reversing Treg-mediated suppression via dendritic cells (DCs). However, deprivation of IL-6 using a neutralizing antibody abrogated the ability of Loxoribin-treated DCs, which reversed the Treg cell-mediated suppression. Furthermore, adoptive transfer of Loxoribin-treated DCs inhibited the tumor growth in vivo. Thus, this study links TLR7 signaling to the functional control of effector T cells and Treg cells and identifies Loxoribin as a new therapeutic strategy in cancer treatment, which may offer new opportunities to improve the outcome of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.